IONS

Business Context and Reporting Period

Company: Isis Pharmaceuticals, Inc. (Note: The filing text identifies the registrant as Isis Pharmaceuticals, Inc., despite the user metadata referencing "IONIS PHARMACEUTICALS INC". The company later changed its name to Ionis in 2011).

Reporting Period: Fiscal year ended December 31, 2008.

Business Overview: Isis is a biopharmaceutical company focused on the discovery and development of antisense drugs. Its strategy involves discovering unique drugs and licensing them to partners for late-stage development and commercialization. Key therapeutic areas include cardiovascular, metabolic, neurodegenerative diseases, and cancer. The company also holds a 51% interest in Regulus Therapeutics, Inc., a joint venture focused on microRNA therapeutics.

Key Financial Metrics

Note: The 2007 Net Loss Applicable to Common Stock included a $125.3 million non-cash charge related to the acquisition of Symphony GenIsis, Inc.

Material Changes vs. Prior Period

• Revenue Growth: Revenue nearly doubled from $58.3 million in 2007 to $107.2 million in 2008. This increase was primarily driven by new collaborations, specifically the strategic alliance with Genzyme (which included a $175 million licensing fee and a $150 million equity investment) and the Regulus/GSK alliance.
• Profitability: While the company reported a net loss of $12.0 million applicable to common stock, management noted that excluding non-cash stock compensation expense, the company finished the year with net income. This contrasts sharply with 2007, which was heavily impacted by the Symphony GenIsis acquisition charge.
• Liquidity: Cash and short-term investments increased significantly to $491.0 million, bolstered by proceeds from Genzyme ($325 million), AMI ($40.5 million), and GSK ($20 million).
• Discontinued Operations: The company sold its Ibis Biosciences subsidiary to Abbott Molecular Inc. (AMI) in January 2009. Consequently, Ibis results are reported as discontinued operations for 2008 and prior periods.

Guidance, Outlook, and Risks

Management Commentary & Outlook

• Pipeline Progress: The lead drug, mipomersen (for cardiovascular disease), is in Phase 3 development with an NDA filing planned for the second half of 2010. The company anticipates adding 3 to 5 new drugs to its pipeline annually.
• Partnerships: Recent partnerships have generated over $650 million in payments with potential future milestones exceeding $2.5 billion.
• Financial Position: Management stated the company exceeded its 2008 cash guidance of $450 million, ending with over $490 million. The sale of Ibis added an additional $175 million to the balance sheet in early 2009.

Risks and Contingencies

• Regulatory Approval: Success depends on obtaining FDA approval for drugs like mipomersen and ISIS 113715. Failure to demonstrate safety or efficacy in late-stage trials could halt commercialization.
• Partner Dependence: The business model relies heavily on corporate partners to fund development and commercialization. If partners fail to fund programs or terminate agreements, the company's business could suffer.
• Intellectual Property: The company faces risks regarding the protection of its patent estate and potential litigation.
• Legal Proceedings: There is an ongoing dispute with Bruker Daltonics regarding the manufacturing and commercialization of the Ibis T5000 System, which was sold to AMI.

Key Facts for Investor Verification

• Mipomersen Timeline: Verify the status of the Phase 3 trials and the projected NDA filing date (H2 2010) for mipomersen, the company's most advanced asset.
• Genzyme Collaboration Terms: Confirm the amortization schedule for the $175 million licensing fee and the $100 million premium on the equity investment, which are being recognized as revenue through June 2012.
• Ibis Sale Earn-outs: Review the earn-out structure for the Ibis sale to AMI, which entitles Isis to 5% of net sales over $140 million (up to $2.1 billion) and 3% thereafter.
• Regulus Financials: Assess the financial performance and burn rate of Regulus Therapeutics, a 51% owned subsidiary, which incurred $10.0 million in operating expenses in 2008.
• Debt Obligations: Verify the terms of the $162.5 million convertible subordinated notes due in 2027 and the potential impact of new accounting standards (FSP No. APB 14-1) on future interest expense.